drugset / Trial / NCT00063206

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

NCT00063206

Phase 3 Completed 247 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Treatment

Summary

Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item \[HAM-D\<sub\>17\</sub\>\] \< 7) versus those subjects receiving placebo.

Timeline

Start
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 100 mg
Subject Desvenlafaxine Other / unclassified 200 mg